Harmony Biosciences Holdings (HRMY) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
2 figures withheld by our checks. Each blank figure names its reason.
59.2mn → 58.5mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
−99.1% YoY in FY25 · 0.0% of revenue.
$0.0M returned vs $347.9M of FCF in FY25. Buybacks covered by cash flow.
18¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 81.8% → 77.2%. Net margin 18.3% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 989,360.0 | 868,453.0 | 714,734.0 | 582,022.0 | 437,855.0 | 305,440.0 | ▲21.5% | +29.9% |
Cost of revenue | 256,941.0 | 198,342.0 | 156,815.0 | 121,236.0 | 83,481.0 | 55,518.0 | ▲26.5% | +37.5% |
Gross profit | 732,419.0 | 670,111.0 | 557,919.0 | 460,786.0 | 354,374.0 | 249,922.0 | ▲20.1% | +28.0% |
Research & development | 237,575.0 | 189,594.0 | 145,825.0 | 76,063.0 | 70,886.0 | 30,367.0 | ▲30.0% | +58.1% |
Selling, general & admin | 145,769.0 | 152,536.0 | 110,352.0 | 95,289.0 | 84,017.0 | 63,909.0 | ▲38.2% | +24.3% |
Total operating expenses | 513,058.0 | 461,642.0 | 367,093.0 | 268,756.0 | 234,188.0 | 162,394.0 | ▲25.8% | +29.8% |
Operating incomefeeds ROC rank | 219,361.0 | 208,469.0 | 190,826.0 | 192,030.0 | 120,186.0 | 87,528.0 | ▲9.2% | +24.2% |
Other income, net | 13,600.0 | 6,595.0 | 978.0 | −18,634.0 | −15,500.0 | −50,100.0 | — | — |
Pretax income | 232,961.0 | 215,064.0 | 191,804.0 | 173,396.0 | 104,686.0 | 37,428.0 | ▲12.1% | +54.8% |
Income tax | 54,360.0 | 56,377.0 | 46,311.0 | 44,543.0 | −76,782.0 | 2,831.0 | ▲21.7% | +111.2% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 178,601.0 | 158,687.0 | 145,493.0 | 128,853.0 | 181,468.0 | 34,597.0 | ▲9.1% | +46.3% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 3.02 | 2.71 | 2.51 | 2.13 | 2.97 | 0.58 | ▲8.0% | +47.0% |
Diluted shares (mn) | 59.68 | 58.54 | 57.87 | 60.37 | 61.10 | 59.21 | ▲1.2% | −0.3% |
| Margins | ||||||||
Gross margin66th pct in Healthcare | 74.0% | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | ▼0.9pp | −4.7pp |
Operating margin | 22.2% | 24.0% | 26.7% | 33.0% | 27.4% | 28.7% | ▼2.7pp | −4.7pp |
Net margin81st pct in Healthcare | 18.1% | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | ▼2.1pp | +6.9pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Harmony Biosciences Holdings' revenue last fiscal year?
Harmony Biosciences Holdings reported revenue of $868.5M in fiscal 2025, up 21.5% from fiscal 2024.
What was Harmony Biosciences Holdings' net income?
Harmony Biosciences Holdings reported net income of $158.7M in fiscal 2025, a net margin of 18.3%.

